Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ponatinib
Drug ID BADD_D01799
Description Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Indications and Usage Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
Marketing Status Prescription
ATC Code L01EA05
DrugBank ID DB08901
KEGG ID D09950
MeSH ID C545373
PubChem ID 24826799
TTD Drug ID D0H0EQ
NDC Product Code Not Available
Synonyms ponatinib | 3-(2-(imidazo(1,2-b)pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-y-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide | ponatinib hydrochloride | AP24534 | AP-24534 | AP 24534 | Iclusig
Chemical Information
Molecular Formula C29H27F3N6O
CAS Registry Number 943319-70-8
SMILES CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
White blood cell count decreased13.01.06.0120.002398%
White blood cell count increased13.01.06.0130.002398%Not Available
Mental status changes19.07.01.0010.000799%Not Available
Mobility decreased17.02.05.018; 15.03.01.003; 08.01.03.0300.001066%Not Available
Ischaemic cardiomyopathy24.04.04.019; 02.04.01.004--Not Available
Peripheral swelling08.01.03.053; 02.05.04.015--Not Available
Chapped lips07.05.01.0040.000533%Not Available
Neutropenic sepsis11.01.11.006; 01.02.03.0070.000139%Not Available
Abasia17.02.05.035; 08.01.02.0070.000799%Not Available
Blood phosphorus decreased13.11.01.015--Not Available
Left ventricular dysfunction02.04.02.011--
Ventricular hypokinesia02.04.02.0130.000799%Not Available
Ejection fraction decreased13.14.02.0030.001066%
Contusion24.07.06.001; 23.03.11.002; 15.03.01.008; 12.01.06.0010.001332%
Musculoskeletal chest pain22.09.01.001; 15.03.04.012--
Deep vein thrombosis24.01.02.0030.001598%Not Available
Post procedural haemorrhage24.07.01.014; 12.02.05.0040.000799%
Malignant neoplasm progression16.16.01.0050.000486%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.0150.000533%Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Vascular occlusion24.04.02.015--Not Available
Blast cell crisis16.01.02.002; 01.10.02.0020.000556%Not Available
Cardiac discomfort02.01.02.011--Not Available
Transaminases increased13.03.01.0150.001598%Not Available
Haemorrhage24.07.01.002--Not Available
Pulmonary mass22.02.07.0040.000799%Not Available
Congestive cardiomyopathy02.04.01.0030.000799%Not Available
Staphylococcal infection11.02.05.0020.000533%Not Available
Angiopathy24.03.02.007--Not Available
The 11th Page    First    Pre   11 12 13 14    Next   Last    Total 14 Pages